CN101129525A - Medicament composition for treating cardiac and cerebral vascular disease - Google Patents
Medicament composition for treating cardiac and cerebral vascular disease Download PDFInfo
- Publication number
- CN101129525A CN101129525A CNA2006100884845A CN200610088484A CN101129525A CN 101129525 A CN101129525 A CN 101129525A CN A2006100884845 A CNA2006100884845 A CN A2006100884845A CN 200610088484 A CN200610088484 A CN 200610088484A CN 101129525 A CN101129525 A CN 101129525A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix notoginseng
- compositions
- breviscapine
- fructus gardeniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating cerebral ischemia, coronary disease and angina pectoris, which comprises cape jasmine 160-1600 weight parts, root of red rooted saliva 160-2500 weight parts, notoginseng 160-1600 weight parts (or notoginsen triterpenes 8-50 weight parts), cape jasmine 160-1600 weight parts and notoginseng 160-1600 weight parts (or notoginsen triterpenes 8-50 weight parts), breviscapine 3-20 weight parts, cape jasmine 160-1600 weight parts, red sage root 160-2500 weight parts and breviscapine 3-20 weight parts.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, specifically refer to any two kinds of medicines are formed in Fructus Gardeniae and Radix Salviae Miltiorrhizae, Radix Notoginseng (or Radix Notoginseng total arasaponins) or the breviscapine pharmaceutical composition and medical usage thereof.These compositionss have the effect of blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, heat and toxic materials clearing away medicine, and energy better protect cardiac-cerebral ischemia tissue injury reduces blood viscosity, delays thrombosis.Can be used for making the medicine of cardiovascular and cerebrovascular diseases such as treatment ischemic encephalopathy, coronary heart disease, angina pectoris.
Background technology
Apoplexy claims " cerebrovascular accident " again, is the focal nervous lesion that a kind of acute non-traumatic local cerebral blood supply obstacle causes, is divided into ischemic and hemorrhagic two big classes.Wherein cerebral infarction is a kind of disease of serious harm senior health and fitness, also is that the old people is disabled and lost the main cause of self care ability.Sickness rate and the mortality rate of apoplexy in China's elderly population all occupies first of the various senile disease.Apoplexy belongs to Chinese medicine " apoplexy " category, and is many owing to wind-phlegm blood stasis, the clear key of stagnation of phlegm etc. cause, controls with blood circulation promoting regulates qi methods such as disperse blood stasis and dredge collateral.
(coronary heart disease CHD) is the abbreviation of coronary heart disease to coronary heart disease.Be a kind of because coronary artery stationarity (atheroma sclerosis) or dynamic property (vasospasm) stenosis or occlusion, the coronary circulation obstacle takes place, cause that myocardial oxygen is unbalance and cause myocardial ischemia-anoxemia or downright bad a kind of heart disease between needing, also claim ischemic heart desease.Coronary heart disease is because its sickness rate height, the mortality rate height, and serious harm human healthy, thereby b referred to as " the first human killers ".
Motherland's medical science thinks that chest arthralgia precordial pain syndrome (coronary heart disease, angina pectoris) is that the deficiency of vital energy is the condition of facilitating blood stasis, so blood stasis due to qi deficiency is the main pathogenesis of coronary heart disease because the stasis of blood hinders venation, brain key, and it is obstructed to cause QI and blood.Thereby the Chinese traditional treatment angina pectoris is often used the medicament of promoting blood circulation to remove obstruction in the collateral, QI invigorating blood stasis dispelling.Chinese patent medicine commonly used has storax pill for treating coronary heart disease, Subing drop pills, SUXIAO JIUXIN WAN, FUFANG DANSHEN PIAN, Radix Salviae Miltiorrhizae drop pill, GUANXIN DANSHEN PIAN, coronary disease sheet, Radix Salviae Miltiorrhizae Tabellae, 'Xuesaitong ' formulation, gingko leaf preparation etc., this class medical instrument has blood circulation promoting and blood stasis dispelling, declares positive blood stasis dispelling, opens the effect that breast eliminates the phlegm, determined curative effect, and long-term use without side effects is for Western medicine institute can not reach.But effective ingredient is clear and definite in these medicaments, steady quality, and determined curative effect, effect is lasting, and the kind of few side effects is still few, has much also to exist technology unreasonable, and the quality standard level is low, is difficult to obtain satisfied curative effect in a large amount of clinical case treatments.
Activating blood circulation to dissipate blood stasis and dredge the collateral is the common method of treatment of motherland's therapeutic treatment coronary heart disease, angina pectoris, apoplexy, Chinese patent medicine commonly used has storax pill for treating coronary heart disease, Subing drop pills, SUXIAO JIUXIN WAN, FUFANG DANSHEN PIAN, Radix Salviae Miltiorrhizae drop pill, GUANXIN DANSHEN PIAN, coronary disease sheet, Radix Salviae Miltiorrhizae Tabellae, 'Xuesaitong ' formulation, gingko leaf preparation, Herba Erigerontis and Breviscapine etc., this class medical instrument has blood circulation promoting and blood stasis dispelling, declares positive blood stasis dispelling, opens the effect that breast eliminates the phlegm, determined curative effect, and long-term use without side effects is for Western medicine institute can not reach.But effective ingredient is clear and definite in these medicaments, steady quality, and determined curative effect, effect is lasting, and the kind of few side effects is still few, has much also to exist technology unreasonable, and the quality standard level is low, is difficult to obtain satisfied curative effect in a large amount of clinical case treatments.Radix Salviae Miltiorrhizae, Radix Notoginseng (or Radix Notoginseng total arasaponins), breviscapine are the definite drug for invigorating blood circulation and eliminating stasis of clinical efficacy, they make up mutually and can effect work in coordination with, as contain the compound red sage root preparations such as FUFANG DANSHEN PIAN, GUANXIN DANSHEN PIAN, DANQI PIAN of Radix Salviae Miltiorrhizae and Radix Notoginseng combination, Radix Notoginseng and breviscapine combination [number of patent application: 03104665], Radix Salviae Miltiorrhizae and breviscapine combination [number of patent application: 200310100812].Fructus Gardeniae is a heat and toxic materials clearing away medicine commonly used, and itself and drug for invigorating blood circulation and eliminating stasis are carried out compatibility, can reach the effect of blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, heat-clearing and toxic substances removing.The combination [number of patent application: 03122071] of existing Fructus Gardeniae and Radix Notoginseng (or Radix Notoginseng total arasaponins) does not have the formulation products of any two kinds of combinations in Fructus Gardeniae and Radix Salviae Miltiorrhizae, Radix Notoginseng (or Radix Notoginseng total arasaponins) or the breviscapine or pertinent literature to report as yet.We carry out prescription according to traditional Chinese medicine theory with them, and by modern pharmacodynamic study, with establish a kind of write out a prescription simple, quality controllable, treat the medicine of cardiovascular and cerebrovascular diseases such as ischemic encephalopathy, coronary heart disease, angina pectoris safely and effectively.
Summary of the invention
The objective of the invention is on the basis of traditional Chinese medicine theory, utilization modern medicine theory, developing a kind of prescription simplifies, quality controllable, the safe and effective medicine compositions specifically refers to: 3 kinds of pharmaceutical compositions that any two kinds of medicines are formed in Fructus Gardeniae and Radix Salviae Miltiorrhizae, Radix Notoginseng (or Radix Notoginseng total arasaponins) or the breviscapine.
Another object of the present invention is to the application in the medicine that these 3 kinds of pharmaceutical compositions can be used for making cardiovascular and cerebrovascular diseases such as treatment ischemic encephalopathy, coronary heart disease, angina pectoris.
Purpose of the present invention can reach by following measure:
Pharmaceutical composition of the present invention is by any two kinds of pharmaceutical compositions that medicine is formed in a component Fructus Gardeniae and b component Radix Salviae Miltiorrhizae, c component Radix Notoginseng (or Radix Notoginseng total arasaponins) or the d component breviscapine.Specifically by any two kinds of pharmaceutical compositions that medicine is formed, i.e. Fructus Gardeniae 160-1600 weight portion and Radix Salviae Miltiorrhizae 160-2500 weight portion, Radix Notoginseng 160-1600 weight portion (or Radix Notoginseng total arasaponins 8-50 weight portion) in Fructus Gardeniae 160-1600 weight portion and Radix Salviae Miltiorrhizae 160-2500 weight portion, Radix Notoginseng 160-1600 weight portion (or Radix Notoginseng total arasaponins 8-50 weight portion) or the breviscapine 3-20 weight portion; Fructus Gardeniae 160-1600 weight portion and Radix Notoginseng 160-1600 weight portion (or Radix Notoginseng total arasaponins 8-50 weight portion), breviscapine 3-20 weight portion; 3 kinds of pharmaceutical compositions of Fructus Gardeniae 160-1600 weight portion and Radix Salviae Miltiorrhizae 160-2500 weight portion, breviscapine 3-20 weight portion.Related active component is the iridoid glycosides of Fructus Gardeniae, the diterpenoid tanshinone class and the salvianolic acid of Radix Salviae Miltiorrhizae, saponins of Radix Notoginseng and breviscapine.
3 kinds of compositionss of the present invention have the effect of blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, heat and toxic materials clearing away medicine; energy better protect cardiac-cerebral ischemia tissue injury; reduce blood viscosity, delay thrombosis, can be used for making the medicine of cardiovascular and cerebrovascular diseases such as treatment ischemic encephalopathy, coronary heart disease, angina pectoris.
Pharmacodynamic study of the present invention is as follows:
Compositions 1: Fructus Gardeniae, Radix Salviae Miltiorrhizae, Radix Notoginseng (or Radix Notoginseng total arasaponins).Compositions 2: Fructus Gardeniae, Radix Notoginseng (or Radix Notoginseng total arasaponins), breviscapine.Compositions 3: Fructus Gardeniae, Radix Salviae Miltiorrhizae, breviscapine.
Experiment 1: to the protective effect of rat cerebral ischemia
The preparation of nylon embolus is with reference to the Zealonga method, and with a long 40mm, an end of the nylon wire of diameter 0.2mm is heated to be slick sphere.Clean and with wipes of alcohol in 18.5mm place, distance pommel labelling, place normal saline standby.
The duplicating and divide into groups to get male SD rat of intraluminal middle cerebral artery occlusion in rats ischemia-reperfusion injury model, body weight 300～350g is divided into 5 groups (each treated animal number sees Table) at random.Be model group (giving isometric normal saline), positive drug group (nimodipine tablet 5mg/kg), compositions 1 extract, compositions 2 extracts and compositions 3 extract groups, gastric infusion is five before operation, and once a day, the administration volume is 10ml/kg.After last administration half an hour with 10% chloral hydrate (300mg/kg, ip) anesthesia, lie on the back on operating-table, neck medisection, separate right carotid (CCA), external carotid artery (ECA), internal carotid artery (ICA), with the branch that No. 0 toe-in is pricked and cut off ECA, separate the outer branch of the cranium pterygoid process arteria palatina of ICA.Folder closes CCA, ICA, and ready nylon embolus is inserted from ECA, goes into cranium to anterior cerebral artery (ACA) through the CCA crotch by ICA, and the nylon wire insertion depth is about 18mm.MCAO draws nylon wire that its pommel is back to outward and can recover middle cerebral artery in the ECA when pouring into again after 4 hours blood supplies.24 hours broken ends are got brain behind the MCAO, and brain was put in the cold saline (2～3 ℃) 10 minutes, remove olfactory bulb, cerebellum and low brain stem after, the crown four blade of cutting is cut into five.First cutter is before brain in the middle of the utmost point and the optic chiasma line; Second cutter is at the optic chiasma position; The 3rd cutter is at the infundibular stalk position; Four blade is between the infundibular stalk and the posterior lobe tail utmost point.Rapidly the brain sheet is put then in the phosphate buffer solution that 5ml contains 1%TTC, the lucifuge temperature was incubated 30 minutes, wherein stirred once every 7～8 minutes, dyed after, normal cerebral tissue is rose, and blocking tissue is white in color, and boundary is clearly demarcated.
Detect index:
(1) cerebral infarct size is measured in TTC dyeing: separate and the infarct area of weighing, obtain infarct weight and account for the heavy percentage ratio of brain, i.e. cerebral infarction rate.
(2) measure cerebral index and brain water content: 24 hours broken ends are got brain behind the MCAO, claim weight in wet base; Dry to constant weight for 106 ℃, promptly dry weight is calculated cerebral index and brain water content by following formula.
Heavy (the g)/body weight (100g) of cerebral index=cutaneous horn
Brain water content (%)=heavy (g) * 100% of [heavy (the g)-brain stem of cutaneous horn heavy (g)]/cutaneous horn
Experimental result (seeing Table 1):
The influence of table 1 pair ischemia-reperfusion rat brain index, brain water content and cerebral infarction rate
| Group | Dosage (g/kg) | Number of animals | Cerebral index (g/100g body weight) | Brain water content (%) | Cerebral infarction rate (%) |
| The positive group of model group compositions 1 compositions 2 compositionss 3 | / 0.005 0.2 0.1 0.15 | 8 8 8 8 8 | 0.53±0.04 0.52±0.04 0.52±0.09 0.55±0.07 0.57±0.06 | 82.44±1.72 80.88±0.96 * 80.57±2.70 81.11±3.15 80.09±2.56 | 28.91±9.94 5.43±2.02 ** 9.60±9.48 ** 9.35±8.10 ** 12.65±5.62 ** |
Annotate: compare with model group:
*P＜0.05,
*P＜0.01
By table 1 as seen, preventive administration is after 5 days, and each compositions has the certain protection effect to the ischemia-reperfusion injury model rat.3 kinds of compositionss have reduction effect trend to brain water content, and 3 kinds of compositionss all can reduce the rat cerebral infarction rate to the ischemia-reperfusion injury model rat, show that each compositions all has certain protective role to the brain injury that causes because of ischemia.
Experiment 2: to the influence of rat platelet function
Get 40 of SD rats, male and female half and half, body weight
200～250g is divided into 5 groups at random, 8 every group, is respectively the blank group, troxerutin positive controls (0.3g/kg), compositions 1 extract group (0.2g/kg), compositions 2 extract groups (0.1g/kg) and compositions 3 extract groups (0.15g/kg).The equal gastric infusion of each administration group, continuous 7d, 1h puts to death rat after the last administration, adopts glass ball method to measure the platelet adhesion rate of rat, the promoting the circulation of blood platelet number of going forward side by side then.Data are represented with mean ± standard deviation, relatively handle (seeing Table 2) with the t check between group.
Each compositions of table 2 to the influence of rat platelet adhesion rate and platelet count purpose (
N=8)
| Group | Dosage/g.kg-1 | Adhesion rate (%) | Platelet count (10 9/L) |
| Blank group troxerutin compositions 1 compositions 2 compositionss 3 | - 0.3 0.2 0.1 0.15 | 35.3±4.3 28.7±3.5 ** 29.1±5.2 ** 27.2±3.7 ** 28.9±5.4 * | 274±25 276±28 285±26 272±32 277±21 |
Compare with the blank group,
*: P＜0.05;
*: P＜0.01.
This experimental result shows that each compositions has tangible reduction effect to the rat platelet adhesion rate, but platelet count is not had obvious influence.
Experiment 3: to the influence of rat thrombus in vivo formation
Get 40 of rats, male and female half and half, body weight 200～240g is divided into 5 groups at random, 8 every group, be respectively the blank group, troxerutin positive controls (0.3g/kg), compositions 1 extract group (0.2g/kg), compositions 2 extract groups (0.1g/kg) and compositions 3 extract groups (0.15g/kg).The equal gastric infusion of each administration group, continuous 7d, 1h after the last administration, pentobarbital sodium 40mg/kg intraperitoneal injection of anesthesia rat, cut skin of neck, separate right carotid artery, place stimulating electrode under the tremulous pulse proximal part, distal end is transferred the temperature probe that connects instrument, open experimental thrombus in vivo and form analyzer), give 1.5mV galvanic stimulation 7min by stimulating electrode, with the damage arterial endothelial cell, along with thrombosis in the arterial lumen forms gradually, blood flow is blocked gradually, the temperature bust, instrument is reported to the police, and record stops up formation time.Data are represented with mean ± standard deviation, relatively handle (seeing Table 3) with the t check between group.
Each compositions of table 3 to the rat thrombus in vivo stop up formation time influence (
N=8)
| Group | Dosage/g.kg-1 | Stop up formation time (min) |
| Blank group troxerutin compositions 1 compositions 2 compositionss 3 | - 0.3 0.2 0.1 0.15 | 10.8±3.6 17.7±3.5** 18.2±3.8* 17.9±4.2** 16.6±3.5* |
Compare with the blank group,
*: P＜0.05;
*: P＜0.01.
This experimental result shows that each compositions has anti-thrombosis function preferably.
Experiment 4: the protective effect of isoproterenol being induced rat myocardium from injury
Randomized is divided into groups rat, about body weight 180g, be divided into 6 groups at random, be that normal group, model group, positive drug are metoprolol group (9mg/kg), compositions 1 extract group (0.2g/kg), compositions 2 extract groups (0.1g/kg) and compositions 3 extract groups (0.15g/kg), 8 every group.Before grouping, measure each Mus electrocardiogram earlier, get rid of the electrocardiographic abnormality person.Irritating stomach except that normal control and model group gives isopyknic distilled water, all the other are respectively organized and irritate the medicinal liquid that stomach gives corresponding dosage equal every day, once a day, continuous 7 days, on 6th except that the normal control group, all the other are respectively organized when the filling stomach gives medicinal liquid or water, a subcutaneous injection isoproterenol 30mg/kg, and measure electrocardiogram after different the third 24 hours in injection, and lactic acid dehydrogenase (LDH) and creatine phosphokinase isoenzyme (CK-MB) level in the serum measured in blood sampling, the content of superoxide dismutase (SOD) vigor and lipid peroxide malonaldehyde (MDA) in the cardiac muscular tissue is measured in the myocardium homogenate of dirty preparation of coring.Each group is traced electrocardiogram before administration, give isoproterenol or normal saline 24h after, replication electrocardiogram, femoral artery blood sampling and win heart and prepare homogenate then.
Each treated animal of detecting ECG writes down normal II lead electrocardiogram, measures to give ST field offset number behind the isoproterenol, and every group of number of animals and ST field offset average that the unusual skew of ST section occurs is as degree of myocardial ischemia with estimate the index of curative effect of medication.
The mensuration of cardiac muscle preparation of homogenate and biochemical indicator is removed residual blood rapidly after winning heart, claims quality, moves in the ice-cold normal saline, and 4 ℃ are ground down and make 10% homogenate.Lactic acid dehydrogenase in the serum (LDH) and creatine phosphokinase isoenzyme (CK-MB) level adopt automatic clinical chemistry analyzer to measure.Cardiac muscle homogenate SOD and lipid peroxide malonaldehyde (MDA) adopt spectrophotometry.
The statistical method data are represented with mean ± standard deviation, relatively handle with the t check between group.
The result
Influence to acute myocardial ischemia rat ECG ST section
Each compositions sees Table 4 to the influence of the ECG ST field offset of acute myocardial ischemia rat.Table 4 demonstration ischemia model group rat is compared with the normal control group, and the ST field offset is apparently higher than normal control group (P＜0.05); And each compositions group and metoprolol positive controls all can significantly reduce the unusual rising (P＜0.05～0.01) of the ST section due to the isoproterenol, this ST section of 4 groups there was no significant difference (P＞0.05) of comparing with the normal control group.
The influence of table 4 pair acute myocardial ischemia rat ECG ST section (
N=8)
| Group | Dosage (mg/kg) | ST section (mm) before the modeling | ST section (mm) after the modeling | Front and back ST difference (mm) |
| 3 groups of 2 groups of compositionss of 1 group of compositions of normal group model group positive drug group compositions | / / 9 200 100 150 | 1.484±0.032 1.473±0.121 1.563±0.164 1.587±0.098 1.627±0.223 1.508±0.241 | 1.454±0.065 * 1.669±0.242 1.481±0.092 * 1.456±0.085 * 1.503±0.074 * 1.480±0.098 * | 0.018±0.081 * 0.196±0.235 -0.081±0.175 * -0.131±0.103 ** -0.124±0.208 * -0.135±0.165 * |
Annotate: with model group than (t-check),
*P＜0.05,
*P＜0.01.
Influence to acute myocardial ischemia rat blood serum LDH and CK-MB
Each compositions sees Table 5 to the influence of acute myocardial ischemia rat blood serum LDH and CK-MB.Obviously increase (P＜0.01～0.001) by visible ischemia model group rat blood serum LDH of table 5 and CK-MB specific activity normal group, and the Serum LDH of each compositions group and CK-MB activity are starkly lower than ischemia model group (P＜0.05).
The influence of table 5 couple acute myocardial ischemia rat blood serum LDH and CK-MB (
N=8)
| Group | Dosage (mg/kg) | LDH(U/L) | CK-MB(U/L) |
| The normal group model group | / / | 1712.3±450.4 *** 2533.4±331.9 | 220.6±39.6 ** 270.6±24.6 |
| 3 groups of 2 groups of compositionss of 1 group of compositions of positive drug group compositions | 9 200 100 150 | 2182.8±272.3 * 2125.8±356.2 * 2143.5±324.2 * 2213.2±318.6 * | 246.1±16.0 * 247.2±17.6 * 242.5±18.6 * 252.7±15.6 * |
Annotate: with model group than (t-check),
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Influence to acute myocardial ischemia rat heart muscle tissue SOD and MDA
Each compositions sees Table 6 to the influence of acute myocardial ischemia rat heart muscle SOD activity and MDA level.Significantly reduce (P＜0.01) by the visible ischemia model group SOD of cardiac muscular tissue of table 6 is active with normal group, MDA content obviously raise (P＜0.001), each compositions group is compared with the ischemia model group, and the SOD activity increases (P＜0.05), and MDA content then obviously reduces (P＜0.01).
The influence of table 6 pair acute myocardial ischemia rat heart muscle tissue SOD and MDA (
N=8)
| Group | Dosage (mg/kg) | SOD vigor (U/mgprot) | MDA level (nmol/mgprot) |
| 3 groups of 2 groups of compositionss of 1 group of compositions of normal group model group positive drug group compositions | / / 9 200 100 150 | 13.07±1.45 ** 11.43±0.89 12.73±1.27 * 14.38±2.35 * 14.24±2.08 * 13.94±2.12 * | 0.99±0.16 *** 1.43±0.21 1.19±0.16 * 0.98±0.21 ** 1.05±0.34 * 1.15±0.18 * |
Annotate: with model group than (t-check),
*P＜0.05,
*P＜0.01,
* *P＜0.001.
This experiment adopts isoproterenol to bring out Model Rats with Acute Myocardial Ischemia, show as ECG ST section and raise unusually, Serum LDH and CK-MB activity obviously increase, and the MDA of cardiac muscular tissue concentration increases, oxygen free radical scavenger SOD is active to be reduced, similar substantially to bibliographical information.Each compositions can be resisted isoproterenol and bring out myocardial ischemia due to the rat, makes the ST section raise degree unusually and reduces, and the LDH level descends in the serum, and ischemic myocardium is had protective effect.This experimental result shows; each compositions can be protected the SOD activity of cardiac muscular tissue; strengthen the function of endogenous oxygen radical removing system, its effect that reduces oxygen-derived free radicals is relevant with the lipid peroxide MDA that membrane lipid generates, and illustrates that each compositions can alleviate oxygen-derived free radicals to induced myocardial injury.
Experiment 1-4 result shows that each compositions has improves cardiac-cerebral ischemia tissue injury preferably, reduces blood viscosity, delays thrombosis, can be used for making the medicine of cardiovascular and cerebrovascular diseases such as treatment ischemic encephalopathy, coronary heart disease, angina pectoris.
The specific embodiment:
Embodiment 1:
The medicinal material extract mode:
When being raw material, need through extracting, with the extract obtained preparation made from Fructus Gardeniae, Radix Salviae Miltiorrhizae or pseudo-ginseng.Can directly feed intake with Radix Notoginseng total arasaponins, when breviscapine is raw material and to make preparation.
The Fructus Gardeniae extracting mode: get Fructus Gardeniae, add 6-8 and doubly measure 60%-90% ethanol, reflux, extract, 2-3 time, merge extractive liquid,, decompression recycling ethanol is done near, promptly gets Fructus Gardeniae extract.
The Radix Notoginseng extracting mode: get Radix Notoginseng, pulverize, add 6-8 and doubly measure 60%-90% ethanol, reflux, extract, 2-3 time, merge extractive liquid,, decompression recycling ethanol is done near, promptly gets Radix Notoginseng extract.
The Radix Salviae Miltiorrhizae extracting mode: get Radix Salviae Miltiorrhizae, add 5-8 and doubly measure the 90%-95% alcohol reflux 2 times, merge alcohol extract, decompression recycling ethanol is done near, gets tanshinol and carries concentrate; Radix Salviae Miltiorrhizae decoction dregs after the alcohol extraction adds 8-15 times of water gaging decoction 2 times, merges the water extract, is evaporated to 1-2g Radix Salviae Miltiorrhizae/ml water liquid, adds ethanol and carries out precipitate with ethanol (60%-80%), gets precipitate with ethanol solution, and decompression recycling ethanol is done near, gets Radix Salviae Miltiorrhizae water and carries concentrate.Merging Radix Salviae Miltiorrhizae alcohol extraction and water are carried concentrate and are promptly got Radix Salviae Miltiorrhizae extract.
Embodiment 2:
Get Fructus Gardeniae 16g, Radix Salviae Miltiorrhizae 16g, Radix Notoginseng 16g (or Radix Notoginseng total arasaponins 0.8g), press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 3:
Get Fructus Gardeniae 25g, Radix Salviae Miltiorrhizae 25g, Radix Notoginseng 25g (or Radix Notoginseng total arasaponins 1.25g), press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 4:
Get Fructus Gardeniae 50g, Radix Salviae Miltiorrhizae 50g, Radix Notoginseng 50g (or Radix Notoginseng total arasaponins 2.5g), press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 5:
Get Fructus Gardeniae 50g, Radix Salviae Miltiorrhizae 100g, Radix Notoginseng 100g (or Radix Notoginseng total arasaponins 5.0g), press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 6:
Get Fructus Gardeniae 160g, Radix Salviae Miltiorrhizae 160g, Radix Notoginseng 160g (or Radix Notoginseng total arasaponins 5g), press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 7:
Get Fructus Gardeniae 16g, Radix Salviae Miltiorrhizae 16g, breviscapine 0.3g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 8:
Get Fructus Gardeniae 25g, Radix Salviae Miltiorrhizae 25g, breviscapine 0.5g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 9:
Get Fructus Gardeniae 50g, Radix Salviae Miltiorrhizae 50g, breviscapine 1.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 10:
Get Fructus Gardeniae 50g, Radix Salviae Miltiorrhizae 100g, breviscapine 1.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 11:
Get Fructus Gardeniae 160g, Radix Salviae Miltiorrhizae 160g, breviscapine 2.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 12:
Get Fructus Gardeniae 16g, Radix Notoginseng 16g (or Radix Notoginseng total arasaponins 0.8g), breviscapine 0.3g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 13:
Get Fructus Gardeniae 25g, Radix Notoginseng 25g (or Radix Notoginseng total arasaponins 1.25g), breviscapine 0.5g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 14:
Get Fructus Gardeniae 50g, Radix Notoginseng 50g (or Radix Notoginseng total arasaponins 2.5g), breviscapine 1.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 15:
Get Fructus Gardeniae 50g, Radix Notoginseng 100g (or Radix Notoginseng total arasaponins 5.0g), breviscapine 1.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Embodiment 16:
Get Fructus Gardeniae 160g, Radix Notoginseng 160g (or Radix Notoginseng total arasaponins 5.0g), breviscapine 2.0g, press embodiment 1 method and extract, it is an amount of that extract adds starch, granulates filled capsules or make 100 in tablet.
Claims (6)
1. one kind by any two kinds of pharmaceutical compositions that medicine is formed in a component and b component, c component or the d component, wherein a component is a Fructus Gardeniae 160-1600 weight portion, the b component is a Radix Salviae Miltiorrhizae 160-2500 weight portion, the c component is Radix Notoginseng 160-1600 weight portion or Radix Notoginseng total arasaponins 8-50 weight portion, and the d component is a breviscapine 3-20 weight portion; Related active component is the iridoid glycosides of Fructus Gardeniae, the diterpenoid tanshinone class and the salvianolic acid of Radix Salviae Miltiorrhizae, saponins of Radix Notoginseng and breviscapine.
2. pharmaceutical composition according to claim 1 is characterized in that the compositions of Fructus Gardeniae 160-1600 weight portion, Radix Salviae Miltiorrhizae 160-2500 weight portion, Radix Notoginseng 160-1600 weight portion or Radix Notoginseng total arasaponins 8-50 weight portion.
3. pharmaceutical composition according to claim 1 is characterized in that the compositions of Fructus Gardeniae 160-1600 weight portion, Radix Notoginseng 160-1600 weight portion or Radix Notoginseng total arasaponins 8-50 weight portion, breviscapine 3-20 weight portion.
4. pharmaceutical composition according to claim 1 is characterized in that the compositions of Fructus Gardeniae 160-1600 weight portion, Radix Salviae Miltiorrhizae 160-2500 weight portion, breviscapine 3-20 weight portion.
5. the application of the pharmaceutical composition of any one qualification of claim 1～4 in preparation treatment ischemic encephalopathy medicine.
6. the application of the pharmaceutical composition of any one qualification of claim 1～4 in preparation treatment coronary heart disease, angina drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100884845A CN101129525A (en) | 2006-08-25 | 2006-08-25 | Medicament composition for treating cardiac and cerebral vascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100884845A CN101129525A (en) | 2006-08-25 | 2006-08-25 | Medicament composition for treating cardiac and cerebral vascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101129525A true CN101129525A (en) | 2008-02-27 |
Family
ID=39127035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100884845A Pending CN101129525A (en) | 2006-08-25 | 2006-08-25 | Medicament composition for treating cardiac and cerebral vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101129525A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002791B (en) * | 2007-01-23 | 2010-04-07 | 胡传良 | Traditional Chinese medicine composition for treating cerebrovascular disease, and its preparing method |
| CN104042754A (en) * | 2014-06-26 | 2014-09-17 | 青岛市市立医院 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
-
2006
- 2006-08-25 CN CNA2006100884845A patent/CN101129525A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002791B (en) * | 2007-01-23 | 2010-04-07 | 胡传良 | Traditional Chinese medicine composition for treating cerebrovascular disease, and its preparing method |
| CN104042754A (en) * | 2014-06-26 | 2014-09-17 | 青岛市市立医院 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN101284050A (en) | Corydalis tuber water-soluble part medicine and preparation method and application thereof | |
| CN103301146A (en) | Traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation | |
| CN101062130B (en) | Yang recuperating decoction soft capsule preparing method | |
| CN100490843C (en) | Prince's-feather preparation and its preparation process and application | |
| CN110075274B (en) | A pharmaceutical composition for treating or preventing nerve injury | |
| CN101129525A (en) | Medicament composition for treating cardiac and cerebral vascular disease | |
| CN102784237A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN101254266B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN102274357B (en) | Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof | |
| CN101342207A (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN100417388C (en) | Compound injection preparation containing ligustrazine and breviscapine and its preparation method | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN106581445A (en) | Traditional Chinese medicine prescription for treating diabetic retinopathy | |
| CN100348206C (en) | Application of speedwell extract in preparing medicine | |
| Degolier et al. | The chronotropic effects of blue cohosh, Caulophyllum thalictroides, on frog hearts in situ and rat hearts in vitro | |
| CN109106767A (en) | A kind of Chinese medicine composition and its preparation method and application for treating hepatitis | |
| CN101176743A (en) | Chinese medicine for curing coronary disease angina pectoris | |
| CN106511881B (en) | A Chinese medicinal composition for invigorating kidney and preventing miscarriage, and its preparation method | |
| CN100348216C (en) | Compound injection from ice tablet and Danshen Root extract and its preparation thereof | |
| CN102743709B (en) | Traditional Chinese medicine preparation for treating wind-evil invasion supraorbital neuralgia and preparation method thereof | |
| CN1879637B (en) | A medicine for treating cardiovascular and cerebrovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080227 |